메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background: The purpose of this study was to compare the outcome of carbapenem versus non-carbapenem antimicrobial therapyfor pediatric urinary tract infections (UTIs) caused by extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae. Materials and Methods: From 2006 to 2011, 42 episodes of UTI caused by ESBL-producing Enterobacteriaceae were diagnosed atSeoul National University Children’s Hospital. Patients were grouped according to the antimicrobials they received into a carbapenemgroup and a non-carbapenem group. Medical records were retrospectively reviewed to assess treatment outcome, time to defervescenceafter initiation of treatment, and relapse rate. Results: There were 36 children with 42 episodes of UTI caused by ESBL-producing Enterobacteriaceae. Twenty-seven cases (64%)had an underlying urologic disease, 28 (67%) cases were caused by Escherichia coli , and 14 (33%) cases were caused by Klebsiellapneumoniae . Four (10%) cases were treated with carbapenem, 23 cases (55%) were treated with non-carbapenem, and 15 (36%)cases were treated by switching from a carbapenem to a non-carbapenem and vice versa. There was no treatment failure at the timeof antimicrobial discontinuation. Between the carbapenem and the non-carbapenem treatment groups, there were no significant differencesin bacterial etiology (P = 0.59), time to defervescence after the initiation of antimicrobials (P = 0.28), and relapse rate (P = 0.50). In vitro susceptibility to non-carbapenem antimicrobials did not affect the time to defervescence after the initiation of antimicrobialtreatment, and the relapse rate in the non-carbapenem group. Conclusions: This study found no significant difference in the treatment outcome between pediatric patients treated with carbapenemand those treated with non-carbapenem antimicrobials for UTI caused by ESBL-producing Enterobacteriaceae. Therefore,the initially administered non-carbapenem can be maintained in UTI patients showing clinical improvement.

목차

등록된 정보가 없습니다.

참고문헌 (20)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0